I am responsible for search, evaluation and in/out-bound transactions including strategic partnerships, licensing transactions, research collaborations and academic partnerships, as well as corporate strategy projects focused on value creation opportunities and long range planning.Successfully led various strategic transactions, including a Commercialization collaboration that out-licensed European and other ex-US territory rights to tab-cel®, an allogeneic T-cell immunotherapy therapeutic. Terms included a $45M upfront payment, $320M in regulatory and sales milestones and significant double-digit royalties.Led extensive follow-on deal process to out-license remaining global development and commercialization rights to tab-cel®, including the US market. Process resulted in an expanded collaboration for global rights, which included ~$30M upfront, $640M in regulatory and sales milestones as well as significant double-digit tiered royalties.Lead key initiatives focused on strategic deal rationale, screening, due diligence, valuation, competitive analyses, deal structuring, negotiations, management of advisors and reviews with executive management.Collaborate with R&D, Technical Operations, Regulatory, Commercial, Finance, Legal and Investor Relations to manage key company initiatives.

As Head of the Halozyme BD & Strategy team, I was responsible for driving external licensing activities for the ENHANZE drug delivery technology through partner identification, opportunity assessment, creation of unique contracting and partnership strategies, oversight of due diligence, relationship management, negotiations, and execution of new deals. Successfully led sell-side efforts on a transaction with a mid-size pharmaceutical company that resulted in a $30M upfront payment, along with up to $500M in downstream milestones and royalties.Identified new potential ENHANZE partners through filtering of relevant databases, utilizing external resources, attending appropriate business development and technical conferences and closely monitoring industry developments, which led to generation of over 50 newly identified partner opportunities.Created and delivered ENHANZE presentations to prospective deal partners, covering introductions to the technology as well as deeper technical overviews which generated over 20 Non-Disclosure Agreements and 6 Material Transfer Agreements.Collaborated with functional leads to ensure alignment and effective communication for diligence activities with internal and external stakeholders, while leading deal partner negotiations, including the development of the value proposition, term sheet and management of the definitive agreement process.Prepared detailed market and company analyses along with financial modeling and deal valuation in support of several potential ENHANZE opportunities.Supported internal efforts to build ENHANZE brand and technology awareness with strategic publication and marketing plans, both for presentations at scientific conferences and publications in the research literature.

Led the Avanir Corporate Development team focused on identification of in-licensing, out-licensing, acquisition, merger and/or co-promotion opportunities, coordination of cross-functional diligence activities, creation of detailed financial analyses, and deal negotiations. Cultivated Business Development projects, including buyer analyses, creation and delivery of pitch decks on Avanir/Otsuka capabilities, communications with external support teams (attorneys, investment bankers, consultants, strategic advisors) and presentation of business cases for executive/Board review. Led two consummated transactions, including a renegotiation of royalties for a pre-launch product, and a strategic long-term supply agreement for an innovative drug-device product. Collaborated with Otsuka to design new governance and operating procedures for global business development.Built financial models, including pro forma P&Ls and NPV estimates of product and company opportunities.Designed and implemented new cross-company process to align on strategic portfolio prioritization efforts across internal pipeline and external development opportunities.Managed Alliance Management responsibilities of Avanir partnerships, including negotiation of key supplier contracts, coordination of cross-company meetings, ensuring performance of license agreement obligations and development of strong cross-company working relationships. Developed, implemented and communicated new Market Intelligence platform to assist cross-functional leadership on keeping informed of company and product news across the neuroscience landscape, along with interpretations on strategic implications to Avanir’s commercial and development programs.

I was the lead finance business partner to the Global Sales & Marketing team for DERMAGRAFT, which included management of two-person staff responsible for financial planning, analysis, and presentations to senior leaders.Created new financial reporting processes and packages including weekly sales reports, monthly close packages, quarterly forecast deliverables and annual LRP/budget submissions.Collaborated with cross-functional leads to support investment decisions and business case presentations on multiple strategic initiatives to the Senior Leadership Team. Coordinated financial diligence on an acquisition opportunity, with responsibilities including a review and analysis of financial and market data and the creation of a P&L model used in the valuation negotiations.Developed key messages, deliverables and Q&A to support Investor Relations with quarterly earnings release.

Developed processes to provide financial planning and analysis for newly launched Biosimilars division, including P&L preparation, cross-functional budgeting, forecasting and long range planning. Collaborated with Biosimilars Business Development lead on creation of potential partnership valuations, in-source and outsource cost/benefit reviews, and modeling of emerging market opportunities. Responsible for extensive financial modeling and presentations to external senior leadership which resulted in a $400M co-development partnership deal between Amgen and Watson Pharmaceuticals.

Led strategic support for Oncology development team, including program specific NPV analyses, guidance on resource allocation and detailed clinical trial cost modeling.Drove monthly close process, budgeting, variance analysis and presentation of results.Developed comprehensive analyses of critical mid-stage pipeline drugs to inform senior management on key financial implications of advancing drugs to late-stage pipeline.

Managed two person team in support of $4 billion business unit, including oversight of monthly close process, annual forecasting and budgeting, and long range planning.

Provided financial, analytical and decision support for Amgen’s first small molecule product launch (SENSIPAR) which enabled eventual progression to blockbuster status.